{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=3&sponsor=Sumitomo+Pharma+America%2C+Inc.",
    "query": {
      "sponsor": "Sumitomo Pharma America, Inc.",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 219,
    "total_pages": 22,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=4&sponsor=Sumitomo+Pharma+America%2C+Inc.&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Sumitomo+Pharma+America%2C+Inc.&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T15:57:05.543Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02275481",
      "title": "A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease (COPD)"
      ],
      "interventions": [
        {
          "name": "Arformoterol tartrate inhalation solution",
          "type": "DRUG"
        },
        {
          "name": "Tiotropium",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2014-11",
      "completion_date": "2016-09-14",
      "has_results": true,
      "last_update_posted_date": "2018-06-27",
      "last_synced_at": "2026-10-09T15:57:05.543Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • Flagstaff, Arizona • Waterbury, Connecticut + 24 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Flagstaff",
          "state": "Arizona"
        },
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02275481"
    },
    {
      "nct_id": "NCT00790023",
      "title": "Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Seasonal Allergic Rhinitis"
      ],
      "interventions": [
        {
          "name": "80 mcg Ciclesonide",
          "type": "DRUG"
        },
        {
          "name": "160 mcg Ciclesonide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 707,
      "start_date": "2008-11",
      "completion_date": "2009-02",
      "has_results": true,
      "last_update_posted_date": "2016-04-08",
      "last_synced_at": "2026-10-09T15:57:05.543Z",
      "location_count": 4,
      "location_summary": "Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Kerrville",
          "state": "Texas"
        },
        {
          "city": "New Braunfels",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00790023"
    },
    {
      "nct_id": "NCT00386334",
      "title": "A Long-Term Safety and Efficacy Study of Eszopiclone in Elderly With Primary Chronic Insomnia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "Eszopiclone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "65 Years to 85 Years"
      },
      "enrollment_count": 388,
      "start_date": "2006-10",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2016-03-14",
      "last_synced_at": "2026-10-09T15:57:05.543Z",
      "location_count": 82,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 69 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00386334"
    },
    {
      "nct_id": "NCT06037668",
      "title": "A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Social Anxiety Disorder (SAD)"
      ],
      "interventions": [
        {
          "name": "BVR-100",
          "type": "DEVICE"
        },
        {
          "name": "BES-100",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 56,
      "start_date": "2023-09-08",
      "completion_date": "2024-01-10",
      "has_results": true,
      "last_update_posted_date": "2025-03-12",
      "last_synced_at": "2026-10-09T15:57:05.543Z",
      "location_count": 6,
      "location_summary": "Orlando, Florida • Boston, Massachusetts • Saint Charles, Missouri + 2 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Saint Charles",
          "state": "Missouri"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06037668"
    },
    {
      "nct_id": "NCT01082263",
      "title": "Midazolam Drug-Drug Interaction Study With Lurasidone HCl",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia Patients"
      ],
      "interventions": [
        {
          "name": "Lurasidone HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2008-10",
      "completion_date": "2008-11",
      "has_results": false,
      "last_update_posted_date": "2011-09-08",
      "last_synced_at": "2026-10-09T15:57:05.543Z",
      "location_count": 1,
      "location_summary": "Culver City, California",
      "locations": [
        {
          "city": "Culver City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01082263"
    },
    {
      "nct_id": "NCT00584974",
      "title": "A Safety, Efficacy and Tolerability Study of SEP-225289",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "SEP-225289",
          "type": "DRUG"
        },
        {
          "name": "Venlafaxine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 523,
      "start_date": "2007-12",
      "completion_date": "2009-05",
      "has_results": false,
      "last_update_posted_date": "2012-02-23",
      "last_synced_at": "2026-10-09T15:57:05.543Z",
      "location_count": 51,
      "location_summary": "Little Rock, Arkansas • Arcadia, California • Beverly Hills, California + 43 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00584974"
    },
    {
      "nct_id": "NCT01451541",
      "title": "A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Perennial Allergic Rhinitis",
        "PAR"
      ],
      "interventions": [
        {
          "name": "Ciclesonide nasal aerosol 37 mcg",
          "type": "DRUG"
        },
        {
          "name": "ciclesonide nasal aerosol 74 mcg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 848,
      "start_date": "2011-10",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2014-05-06",
      "last_synced_at": "2026-10-09T15:57:05.543Z",
      "location_count": 60,
      "location_summary": "Hot Springs, Arkansas • Little Rock, Arkansas • Costa Mesa, California + 51 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01451541"
    },
    {
      "nct_id": "NCT07444268",
      "title": "How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Hematologic Malignancies"
      ],
      "interventions": [
        {
          "name": "DSP-5336",
          "type": "DRUG"
        },
        {
          "name": "[14C]-DSP-5336",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2026-03-26",
      "completion_date": "2026-09-04",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-09T15:57:05.543Z",
      "location_count": 2,
      "location_summary": "Chapel Hill, North Carolina • Houston, Texas",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07444268"
    },
    {
      "nct_id": "NCT05491525",
      "title": "Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Neurogenic Detrusor Overactivity"
      ],
      "interventions": [
        {
          "name": "Vibegron",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Urovant Sciences GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 71,
      "start_date": "2022-10-12",
      "completion_date": "2030-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-09T15:57:05.543Z",
      "location_count": 11,
      "location_summary": "Little Rock, Arkansas • Orange, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05491525"
    },
    {
      "nct_id": "NCT00866775",
      "title": "Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy With Simple or Complex Partial Onset Seizures"
      ],
      "interventions": [
        {
          "name": "Eslicarbazepine acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "16 Years to 70 Years"
      },
      "enrollment_count": 193,
      "start_date": "2009-04",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2016-03-11",
      "last_synced_at": "2026-10-09T15:57:05.543Z",
      "location_count": 103,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Northport, Alabama + 82 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Northport",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00866775"
    }
  ]
}